186 related articles for article (PubMed ID: 30349208)
41. Identifying Patient-Centered Research Priorities in Overactive Bladder by Crowdsourcing and Targeted Recruitment.
Park A; Kennedy A; Kennedy R; Zimmern PE; Malik RD
Urol Pract; 2022 May; 9(3):246-252. PubMed ID: 37145539
[TBL] [Abstract][Full Text] [Related]
42. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
Patient; 2012; 5(1):33-44. PubMed ID: 22077619
[TBL] [Abstract][Full Text] [Related]
43. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
[TBL] [Abstract][Full Text] [Related]
44. Patient-reported reasons for discontinuing overactive bladder medication.
Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with clinical assessment of overactive bladder and selection of treatment.
Diokno A; Lee P; Zorn BH; Lenderking WR; Grossman MA; Bull SA; Albrecht D
Clin Ther; 2001 Sep; 23(9):1542-51. PubMed ID: 11589266
[TBL] [Abstract][Full Text] [Related]
46. Patient preferences for objective quality metrics during community pharmacy selection: A discrete choice experiment.
Patterson JA; Holdford DA; Harpe SE
Res Social Adm Pharm; 2019 Jun; 15(6):641-649. PubMed ID: 30143466
[TBL] [Abstract][Full Text] [Related]
47. Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.
Mansfield C; Thomas N; Gebben D; Lucas M; Hauber AB
Int J MS Care; 2017; 19(4):172-183. PubMed ID: 28835741
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study.
Shawahna R; Hijaz H; Jallad K; Abushamma M; Sawafta M
BMC Urol; 2021 Oct; 21(1):142. PubMed ID: 34625087
[TBL] [Abstract][Full Text] [Related]
49. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
50. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
51. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction?
Juliato CRT; Melotti IGR; Junior LCS; Britto LGO; Riccetto CLZ
J Sex Med; 2017 Jul; 14(7):904-909. PubMed ID: 28622875
[TBL] [Abstract][Full Text] [Related]
52. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan.
Komine M; Kim H; Yi J; Zhong Y; Sakai Y; Crawford B; Habiro K; Hikichi Y; Feldman SR
J Dermatol; 2023 Jun; 50(6):766-777. PubMed ID: 36808765
[TBL] [Abstract][Full Text] [Related]
53. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
54. [Economic impact of overactive bladder symptoms in Japan].
Inoue S; Kobayashi M; Sugaya K
Nihon Hinyokika Gakkai Zasshi; 2008 Nov; 99(7):713-22. PubMed ID: 19068687
[TBL] [Abstract][Full Text] [Related]
55. Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment.
King-Concialdi K; Beusterien K; Senglaub SS; Will O; Jaffe DH; Patel MY; Harrison MR
Patient Prefer Adherence; 2023; 17():2237-2248. PubMed ID: 37706208
[TBL] [Abstract][Full Text] [Related]
56. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
57. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population.
Lai HH; Shen B; Rawal A; Vetter J
BMC Urol; 2016 Oct; 16(1):60. PubMed ID: 27716241
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
[TBL] [Abstract][Full Text] [Related]
59. Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.
Tran K; Levin RM; Mousa SA
Adv Urol; 2009; 2009():345324. PubMed ID: 20029638
[TBL] [Abstract][Full Text] [Related]
60. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
